Substituted esters as cannabinoid-1 receptor modulators

Details Substituted esters as cannabinoid-1 receptor modulators Substituted esters as cannabinoid-1 receptor modulators

C - Chemistry, Metallurgy

07

C

C07C 255/60 (2006.01) A61K 31/277 (2006.01) A61K 31/395 (2006.01) C07D 213/79 (2006.01) C07D 231/14 (2006.01) C07D 239/00 (2006.01) C07D 241/00 (2006.01) C07D 261/00 (2006.01) C07D 285/06 (2006.01) C07D 403/12 (2006.01) C07D 495/00 (2006.01)

Patent

CA 2652259

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer~s disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson~s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

De nouveaux composés ayant la formule structurale (I) sont des antagonistes et/ou agonistes inverses du récepteur Cannabinoïde-1 (CB1) et sont utiles dans le traitement, la prévention et la suppression de maladies véhiculées par le récepteur CB1. Les composés de la présente invention sont utiles en tant que médicaments agissant centralement dans le traitement de la psychose, des déficiences de la mémoire, des troubles cognitifs, de la maladie d'Alzheimer, de la migraine, de la neuropathie, des troubles neuro-inflammatoires y compris la sclérose en plaques et le syndrome de Guillain-Barré et des séquelles inflammatoires de l'encéphalite virale, des accidents vasculaires cérébraux, et du traumatisme crânien, des troubles d'anxiété, du stress, de l'épilepsie, de la maladie de Parkinson, des troubles du mouvement et de la schizophrénie. Les composés sont également utiles pour le traitement des troubles liés à la toxicomanie, le traitement de l'obésité ou des troubles de l'alimentation, ainsi que le traitement de l'asthme, de la constipation, de la pseudo-obstruction intestinale chronique, de la cirrhose du foie, de la maladie de la stéatose hépatique non alcoolique (NAFLD), de la stéatohépatite non alcoolique (NASH) et la promotion de la vigilance.

Affiliated with

Also associated with

Rating

Substituted esters as cannabinoid-1 receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted esters as cannabinoid-1 receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted esters as cannabinoid-1 receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1392161